PUBLISHER: The Business Research Company | PRODUCT CODE: 1641655
PUBLISHER: The Business Research Company | PRODUCT CODE: 1641655
Biosimulation is a mathematical simulation process that uses computers to replicate biological processes and systems. The aim of biosimulation is a model-based prediction of the dynamics and behavior of biological systems.
The main types of products in the biosimulation market are software and services. The biosimulation software provides software for molecular modelling and simulation, pharmacokinetic/pharmacodynamic (PK/PD) modelling and simulation, toxicity prediction software, physiologically based pharmacokinetic modeling, and simulation (PBPK) modelling and simulation, trial design software, and others. It is used in drug development, drug discovery, and others and implemented in various verticals such as pharmaceutical and biotechnology companies, contract research organizations (CROs), regulatory authorities, academic research institutions, others.
The biosimulation market research report is one of a series of new reports from The Business Research Company that provides biosimulation market statistics, including biosimulation industry global market size, regional shares, competitors with a biosimulation market share, detailed biosimulation market segments, market trends and opportunities, and any further data you may need to thrive in the biosimulation industry. This biosimulation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The biosimulation market size has grown rapidly in recent years. It will grow from $4.47 billion in 2024 to $5.02 billion in 2025 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to growing complexity of diseases, rise of in silico trials, drug development cost reduction, growing complexity of diseases, rising prevalence of chronic diseases.
The biosimulation market size is expected to see rapid growth in the next few years. It will grow to $9.65 billion in 2029 at a compound annual growth rate (CAGR) of 17.8%. The growth in the forecast period can be attributed to biosimulation in rare disease research, focus on pharmacodynamics modeling, patient stratification in clinical trials, rapid growth in biopharmaceuticals, biosimulation for drug repurposing, demand for safer and more efficacious drugs. Major trends in the forecast period include digital r&d strategies, technological advancements in simulation software, biosimulation for biomarker identification, optimization of clinical trial design, digital biomarkers and endpoints, continuous advancements in computational biology.
The rise in global healthcare expenditure is expected to bolster the biosimulation market during the forecast period. Increased healthcare spending is anticipated to lead to higher investments in drug development, thereby boosting the revenue generated from biosimulation solutions. Biosimulation software is increasingly being utilized in drug development to simulate diseases. This technology enables virtual clinical trials for new pharmaceutical drugs by using computers to run disease simulations. For example, in July 2024, the American Medical Association, a US-based organization, reported that U.S. healthcare spending increased by 4.1% in 2022, reaching $4.5 trillion, or $13,493 per person. Therefore, the surge in healthcare expenditure is driving the growth of the biosimulation market.
The rising prevalence of chronic diseases is expected to propel the growth of the biosimulation market going forward. Chronic diseases are medical conditions that persist over an extended period of time, often for a person's lifetime. Biosimulation plays a crucial role in understanding the complex mechanisms underlying chronic diseases, aiding in drug development and personalized treatment strategies. For instance, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 41 million fatalities, constituting 74% of the total deaths attributed to non-communicable diseases (NCDs) or chronic conditions worldwide each year. These fatalities encompassed 17. 9 million deaths due to cardiovascular diseases, 9. 3 million deaths related to cancer, 4. 1 million deaths associated with chronic respiratory diseases, and 2.0 million deaths from diabetes. Therefore, the rising prevalence of chronic diseases is driving the growth of the biosimulation market.
Product innovation is becoming a key trend in the biosimulation market, with several companies focusing on developing new and advanced solutions. For example, in June 2023, Certara, Inc., a Pennsylvania-based company that accelerates drug development using proprietary biosimulation software, technology, and services, launched its new Phoenix Biosimulation Software. This software enhances pharmacokinetic (PK) and pharmacodynamic (PD) modeling, improving the efficiency of drug development while reducing costs. It achieves this through streamlined workflows and integrated data analysis tools, offering a more efficient approach to traditional drug discovery and development.
Major companies operating in the biosimulation market are focusing on cloud-based biosimulation to gain a competitive edge in the market. Cloud-based biosimulation software enables researchers to model and analyze complex biological processes remotely, facilitating collaboration and scalability in life sciences. For instance, in October 2023, Optibrium, a UK-based developer of software solutions for small molecule design, optimization, and data analysis, launched a cloud-based version of its drug discovery platform, StarDrop. The updated version maintains the full range of features and user engagement found in the desktop application. Additionally, it enhances accessibility and reduces the overall cost of ownership for clients. StarDrop, now cloud-based, is accessible from any internet-connected device, offering users a flexible way to utilize the software.
In September 2022, Cadence Design Systems Inc., a US-based computer software company acquired OpenEye Scientific Software for an undisclosed amount. With this acquisition Cadence Design Systems, Inc. is focusing on enhancing its capabilities in the field of computational molecular modeling and simulation, particularly within the realm of drug discovery and design. OpenEye Scientific Software is a US-based software company providing bio simulations software tools.
Major companies operating in the biosimulation market include Certara Inc., Dassault Systemes SE, Schrodinger Inc., Simulations Plus Inc., Rhenovia Pharma SAS, Insilico Biotechnology AG, Genedata AG, Entelos Inc., Physiomics plc, Rosa & Co. LLC., In Silico Biosciences Inc., INOSIM Software GmbH, LeadInvent Technologies Limited, Nuventra Pharma Sciences Inc., Archimedes Inc., VeriSIM Life Inc., Compugen Inc., Leadscope Inc., Pharmaceutical Product Development LLC, Advanced Chemistry Development Inc., Chemical Computing Group Inc., Immunetrics and PPD Inc., Instem India Private Limited, Evidera Inc., Biomodels LLC, PhysioStim SA, Lhasa Limited, SimBioSys Inc., Cadence Design Systems Inc., Allucent Inc.
North America was the largest region in the biosimulation market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimulation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the biosimulation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
The biostimulation market includes revenues earned by entities by providing stimulation technology that provide simulations of biological processes and predict the behavior of biological systems to enhance the research and development (R&D) process. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Biosimulation Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on biosimulation market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for biosimulation ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biosimulation market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.